Business Wire

Significant Breakthroughs in Preserving ALS Lung Function and Survival Unveiled in Peer-Reviewed Studies of Novel Immunotherapy Platform NP001

PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...
Business Wire

Mounting Evidence Demonstrates Neuvivo’s NP001 Spares Lung Function and Substantially Extends Survival in ALS Patients

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...